| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CLINICAL STUDY |
Division of Clinical Sciences North, University of Sheffield, Northern General Hospital, Sheffield S5 7AU, UK
(Correspondence should be addressed to J Newell-Price; Email: j.newellprice{at}sheffield.ac.uk)
Background: The excess mortality and morbidity associated with acromegaly are secondary to prolonged elevation of GH and IGF-I. Vigorous control of these biochemical parameters results in improved morbidity and mortality. Somatostatin analogues (SAs) allow adequate control of GH and IGF-I in approximately 65% of subjects, leaving a significant cohort uncontrolled. Dopamine agonists (DAs), a cheap alternative to SAs, allow control of GH and IGF-I in less than 20% of patients with acromegaly.
Aims: To assess the effectiveness of adding DA therapy to SA in the biochemical control of acromegaly.
Subjects: One hundred and twenty cases from the Sheffield Acromegaly Register were reviewed; 24 (20%) did not require medical treatment following pituitary surgery alone; 16 (13%) had safe GH levels following surgery and radiotherapy; and 58 (48%) required medical treatment despite having had surgery, radiotherapy or both. The remaining 22 (18%) received only medical treatment.
Methods: In nine subjects a DA (three bromocriptine, six cabergoline) was added to an SA to control active disease. GH day curves and IGF-I levels were compared before and after the addition of a DA to existing SA treatment. All were on stable maximum-dose treatment with an SA, with inadequate biochemical control prior to addition of DA therapy. Mean duration of treatment on a DA before biochemical assessments were made was 10.3 months. Six subjects had previously been treated with either transsphenoidal surgery, radiotherapy or both. In three subjects SA was the primary therapy.
Results: All subjects exhibited a fall in median GH and IGF-I levels. Introduction of a DA resulted in a 36.1% reduction in median GH levels (8.3 vs 5.3 mIU/l; P = 0.008) on a GH day curve and a 35.2% reduction in IGF-I levels (387.2 vs 251.0 µg/l; P = 0.018). Only four subjects had elevated prolactin levels prior to the addition of a DA (>368 mIU/l).
Conclusion: Addition of DAs to SAs is of benefit in the biochemical control of acromegaly and should be considered in those inadequately controlled. Furthermore, the beneficial effects of DAs occur even when pre-treatment prolactin levels are within the normal range.
This article has been cited by other articles:
|
|
 |
|
  V J Moyes, K A Metcalfe, and W M Drake Clinical use of cabergoline as primary and adjunctive treatment for acromegaly Eur. J. Endocrinol., November 1, 2008; 159(5): 541 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ferone, W. W. de Herder, R. Pivonello, J. M. Kros, P. M. van Koetsveld, T. de Jong, F. Minuto, A. Colao, S. W. J. Lamberts, and L. J. Hofland Correlation of in Vitro and in Vivo Somatotropic Adenoma Responsiveness to Somatostatin Analogs and Dopamine Agonists with Immunohistochemical Evaluation of Somatostatin and Dopamine Receptors and Electron Microscopy J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1412 - 1417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Abrams, O. Alexopoulou, R. Abs, D. Maiter, and J. Verhelst Optimalization and cost management of lanreotide-Autogel therapy in acromegaly Eur. J. Endocrinol., November 1, 2007; 157(5): 571 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Colao, M. Filippella, R. Pivonello, C. Di Somma, A. Faggiano, and G. Lombardi Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S57 - S63. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
